As consumers, we trust that the pharmaceuticals we take are safe and effective. Unfortunately, that is not always the case. Throughout the course of history, many large pharmaceutical companies have reached substantial settlements with individuals and their families after some pharmaceuticals were found to have harmful and unforeseen side effects. Here, the pharmaceutical liability attorneys […]
In July 2019, pharmaceutical manufacturer Allergan ordered a recall of its BIOCELL textured breast implants after reports that the implants were linked to a serious cancer affecting hundreds of patients. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss recent updates to this serious event as well as your legal options if you have […]
For the first time in 16 years, a drug combination and FDA-approved systemic therapy has been approved to treat malignant pleural mesothelioma that cannot be removed surgically. The first-line treatment for adults will include drug combination therapy using Opdivo (nivolumab) and Yervoy (ipilimumab) to increase the chances of patient survival. Here, the pharmaceutical liability attorneys […]
On September 23rd, the U.S. Food and Drug Administration (FDA) announced that it would be requiring “class-wide labeling changes” for psychoactive drugs that fall under the class of Benzodiazepines. The label change to the Boxed Warning will include benzos’ risks of abuse, dependence, misuse, addiction and potential withdrawal symptoms. The labeling update is a reaction […]
On September 24th, 2020, the FDA published a press release issuing updated recommendations regarding the potential risks of mercury-containing dental amalgam fillings to high-risk groups. The FDA is issuing these updates as a response to certain risks surrounding the dental fillings that may predominantly impact certain high-risk groups. Dental Amalgam is a Substance Used to […]
On April 1st, the Food and Drug Administration (FDA) announced its request for all prescription and over-the-counter ranitidine drugs to be removed from the market immediately. This decision was made based on an ongoing investigation of possible carcinogenic effects of the contaminant N-nitrosodimethylamine, or NDMA. Here, the pharmaceutical liability attorneys at Peter Angelos Law discuss […]
Global health regulators have raised the alarm about the possibility that the widely used drug, Zantac, could be tainted with the same cancer-causing agent found in Valsartan earlier this year. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos detail the preliminary results of the FDA and EU probes. Officials are Investigating […]
A recent study investigated a potential link between a Type-2 diabetes drug and a severe and potentially fatal necrotizing fasciitis called Fournier gangrene. Here, the pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss the recent study and how SGLT2 inhibitors may potentially be linked to the development of Fournier gangrene. The First […]
Zostavax, a vaccine administered to protect against herpes zoster, otherwise known as shingles, is now being contested in approximately 550 cases in multidistrict litigation (MDL). Here, the Baltimore pharmaceutical liability attorneys at The Law Offices of Peter Angelos discuss updates in Zostavax litigation for 2019. Zostavax was Intended to Weaken the Shingles Virus When Zostavax […]
In June of 2016, antipsychotic pharmaceutical drug Nuplazid was approved as a new method of treating psychosis in Parkinson’s patients. Since it’s release over two years ago, concern has arose regarding the drug, with some claiming it was released before more stringent testing could be completed and others concerned that the possible side effects of […]